2026-10-28Bullish
+6.62%24 hours changeQ3 adjusted EPS of $1.34 beat the $1.21 Zacks consensus by 10.7% and full-year adjusted EPS guidance was raised to $4.95–5.05.
read the report →Develops, manufactures and markets medical products, services and digital solutions for diagnosis, treatment and monitoring, across Imaging, Advanced Visualization, Patient Care and Pharmaceutical Diagnostics segments.
stitched from the price window carried by each report
Q3 adjusted EPS of $1.34 beat the $1.21 Zacks consensus by 10.7% and full-year adjusted EPS guidance was raised to $4.95–5.05.
read the report →GE HealthCare surged after beating Q2 2026 earnings and revenue estimates while reporting record order backlog growth.
read the report →